You are here

Vas Narasimhan

Amid major restructuring, Novartis CEO Narasimhan’s 2022 pay fell by more than a quarter

Amid major restructuring, Novartis CEO Narasimhan’s 2022 pay fell by more than a quarter

Fierce Pharma

Flag link:

Novartis CEO, as incoming PhRMA chair, outlines 3 priorities for pharma after IRA setback

Novartis CEO, as incoming PhRMA chair, outlines 3 priorities for pharma after IRA setback

Fierce Pharma

Inflation Reduction Act

small molecule drugs

Flag link:

Novartis CEO says Covid likely to become endemic, urges investment in pandemic preparedness

Novartis CEO says Covid likely to become endemic, urges investment in pandemic preparedness

CNBC

Flag link:

What is Novartis without Sandoz? Vas Narasimhan is 'patient' as new company takes form

What is Novartis without Sandoz? Vas Narasimhan is 'patient' as new company takes form

Endpoints

Flag link:

Vas Narasimhan and Severin Schwan each claimed pay packets worth $12M+ for 2021

Vas Narasimhan and Severin Schwan each claimed pay packets worth $12M+ for 2021

Endpoints

Flag link:

No news anytime soon on Sandoz sale, says Novartis

No news anytime soon on Sandoz sale, says Novartis

Pharmaforum

Flag link:

Now reimagining home, office schedules: Novartis CEO Vas Narasimhan sees a new normal in the post-Covid era

Now reimagining home, office schedules: Novartis CEO Vas Narasimhan sees a new normal in the post-Covid era

Endpoints

Flag link:

Novartis CEO's 2020 pay drops to $11.6M, no thanks to COVID-19's drag on sales

Novartis CEO's 2020 pay drops to $11.6M, no thanks to COVID-19's drag on sales

Fierce Pharma

Flag link:

Novartis CEO: COVID-19 vaccine might take until end of 2021 to reach patients

Novartis CEO: COVID-19 vaccine might take until end of 2021 to reach patients

Fierce Pharma

Flag link:

Vas Narasimhan wants Novartis to have a big focus on China. Here’s what that looks like

Vas Narasimhan wants Novartis to have a big focus on China. Here’s what that looks like

Endpoints

Flag link:

JPM: New Novartis pharma chief rethinks its drug-launch formula

JPM: New Novartis pharma chief rethinks its drug-launch formula

Fierce Pharma

Flag link:

JPM: With new ethics plan, Novartis chief puts his money where his mouth is

JPM: With new ethics plan, Novartis chief puts his money where his mouth is

Fierce Pharma

Flag link:

Novartis says mid-stage pipeline is setting up strong growth spurt

Novartis says mid-stage pipeline is setting up strong growth spurt

Pharmaforum

clinical trials

Flag link:

Novartis Makes New Data Integrity Commitment

Novartis Makes New Data Integrity Commitment

RAPS.org

Flag link:

AveXis scientific founder fires back at Novartis CEO Vas Narasimhan, 'categorically denies any wrongdoing'

AveXis scientific founder fires back at Novartis CEO Vas Narasimhan, 'categorically denies any wrongdoing'

Endpoints

Flag link:

Novartis CEO Says FDA Process Could Have Been Handled Better

Novartis CEO Says FDA Process Could Have Been Handled Better

Bloomberg

Flag link:

Novartis' $18.5B in M&A under Vas Narasimhan says a lot about their careful — but opportunistic — deal strategy

Novartis' $18.5B in M&A under Vas Narasimhan says a lot about their careful — but opportunistic — deal strategy

Endpoints

Flag link:

Novartis chief Vas Narasimhan wants you to know about the '25-plus’ blockbusters he has in the pipeline

Novartis chief Vas Narasimhan wants you to know about the '25-plus’ blockbusters he has in the pipeline

Endpoints

Flag link:

Novartis CEO plans gene therapy price 'far lower' than $4 million to $5 million range

Novartis CEO plans gene therapy price 'far lower' than $4 million to $5 million range

Yahoo/Reuters

Flag link:

Commentary: Novartis CEO: Gene therapy offers hope of cures in one treatment, but US needs new pricing and payment model

Commentary: Novartis CEO: Gene therapy offers hope of cures in one treatment, but US needs new pricing and payment model

CNBC

Flag link:

Pages